| Name | Title | Contact Details |
|---|---|---|
David Fein |
Director of Marketing Technologies | Profile |
Mid-Atlantic Dental Partners delivers dental services through a partnership with dentists who are respected in their communities.
More commonly known as Columbia County Health System and Dayton General Hospital, the Columbia County Public Hospital District #1 was established in 1960 with the vision and mission of providing high quality healthcare to our local communities. We are a 25-bed, Critical Access Hospital with Level V Trauma Center, Level III Cardiac and Stroke Center designations. Additionally, we are the regions primary wound care and hyperbaric therapy treatment center. Our primary service areas include Dayton, Waitsburg, Starbuck, and the surrounding region. We are comprised of Columbia Family Clinic, Waitsburg Clinic, Booker Rest Home, and Dayton General Hospital with our Rural Health Clinics open for primary care and behavior health services 6 days a week. We are fully staffed with 3 primary care medical doctors, a board-certified emergency medicine doctor, a board-certified pediatrician, 4 mid-level family practice providers, and dermatology focused ARNP. Our Emergency Department is staffed with our employed providers as well as partner physicians. In addition to Acute Care services, we offer inpatient care for sub-acute, Swing Bed patients, which are patients that need a step down from acute care, but still require skilled nursing care and/or various rehabilitation therapies for an extended period. This service allows patients, who may have had a qualifying, Acute hospitalization or surgery, to return to our facility and receive hospital class nursing and rehabilitation services for an extended period.
The Sibery Group LLC is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
sbifinechemicals is a EDMONTON, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.